KINGDOM OF SAUDI ARABIA
Northern Border University (NBU)
Journal of the North for Basic & Applied Sciences(JNBAS)
p - ISSN : 1658 -7022 / **e-ISSN:** 1658 - 7014
www.nbu.edu.sa
s.journal@nbu.edu.sa

Emerging Insights on Probiotics and Their Functional Benefits for Human Health

Fanar Hamad Alshammari
Department of Biological Science, Northern Border University Arar, Saudi Arabia.

(**Received:** 7th December 2025; **Accepted:** 19th Jan 2026)

Abstract
Probiotics have emerged as a central component of strategies aimed at improving human health through modulation of the gut microbiome. Growing evidence demonstrates that specific bacterial and yeast strains exert diverse functional benefits, ranging from enhancing gastrointestinal stability to regulating immune, metabolic, dermatological, and neuropsychological processes. This review reports current insights into mechanisms and therapeutic applications of probiotics, highlighting how these microorganisms promote colonization resistance, strengthen the intestinal barrier, modulate inflammatory and oxidative pathways, and influence gut–brain–skin communication. We summarize the most clinically relevant probiotic strains and their documented benefits across major health conditions, including digestive disorders, metabolic dysfunction, immune dysregulation, skin inflammation, and mental health. Furthermore, we discuss the safety considerations, regulatory landscape, and future directions in developing next-generation probiotics and personalized microbiome-based interventions. By integrating mechanistic understanding with clinical evidence, this review provides a comprehensive yet concise resource for advancing probiotic research and guiding their effective use in human health.

Keywords: Probiotics; Gut microbiota; Immune modulation; Metabolic regulation; Microbiome therapies; Next-generation probiotics

(*) **Corresponding Author**:
Fanar Hamad Alshammari.
Department of Biological Science, Northern Border University Arar, Saudi Arabia.
E-mail: fanar.alshammari@nbu.edu.sa

DOI: 10.12816/0062501

1. Introduction

Probiotics have emerged as one of the most dynamic and influential areas of biomedical and nutritional research, largely due to their profound ability to interact with the human microbiome and shape health outcomes across multiple physiological systems [1]. Historically, probiotics were understood primarily through their use in fermented foods and their association with digestive benefits [2]. However, advances in microbiome sequencing technologies, systems biology, and clinical research have significantly expanded our understanding of these microorganisms [3]. Probiotics are now recognized not merely as digestive aids but as biologically active agents capable of modulating metabolism, immunity, neurological signaling, and dermatological responses [4]. As scientific interest intensifies, probiotics have evolved from traditional dietary components into promising therapeutic candidates that hold relevance in both preventive health and disease management [5].

Our understanding of probiotics has broadened in parallel with discoveries regarding the human gut microbiota, a complex ecosystem that influences nearly every aspect of host physiology [6]. Disruptions to this microbial environment-referred to as dysbiosis-have been associated with numerous chronic conditions, including inflammatory bowel disease, irritable bowel syndrome, metabolic syndrome, obesity, type 2 diabetes, cardiovascular disorders, skin inflammation, and mental health disturbances [7]. Probiotics, through their strain-specific functions, play an essential role in restoring microbial balance and preventing or mitigating the consequences of dysbiosis [8]. Their biological effects extend beyond the gut, highlighting intricate communication pathways such as the gut–brain axis, gut–skin axis, and gut–immune interface [9]. These interconnected systems provide a compelling rationale for examining probiotics not only within gastrointestinal health but as modulators of systemic homeostasis.

In recent years, research has intensified around the molecular and cellular mechanisms underlying probiotic functions [10]. Probiotics can influence the host through multiple pathways, including competitive exclusion of pathogens, enhancement of epithelial barrier integrity, synthesis of antimicrobial metabolites, modulation of inflammatory and oxidative stress pathways, and regulation of host immune signaling [11]. Certain strains can produce neurotransmitter-active compounds, enabling communication with the central nervous system, while others participate in lipid metabolism, glycemic control, and lipid-lowering processes. These multifaceted interactions underscore the importance of understanding the mechanisms of action at strain-specific and molecular levels, as the functional diversity among probiotic species and strains directly influences therapeutic outcomes.

The clinical relevance of probiotics continues to grow as evidence accumulates from randomized controlled trials, meta-analyses, and translational research [12]. Probiotics have demonstrated benefits in managing digestive disorders and antibiotic-associated diarrhea; improving metabolic markers related to obesity, cholesterol regulation, and insulin sensitivity; enhancing immune resilience; reducing inflammatory skin conditions; and supporting psychological well-being [13]. While not all strains exert the same effects, and clinical findings can vary based on dose, formulation, and host factors, the overall trajectory of evidence points to probiotics as powerful modulators of health [1]. Despite their widespread use and promising potential, important challenges remain [14]. Variability in strain efficacy, lack of standardization in manufacturing, inconsistent regulatory frameworks, and limited understanding of long-term safety and host-microbe interactions highlight the need for continued research and refinement [15]. Moreover, the emergence of next-generation probiotics and engineered microbial therapeutics introduces new opportunities and complexities in the field. Against this backdrop, a comprehensive review that consolidates existing evidence, highlights mechanistic insights, examines clinical applications, and outlines safety and future research priorities is essential to guide effective use and inform scientific advancement [16].

This review aims to synthesize current knowledge on the classification, characteristics, and mechanisms of probiotics; examine their functional benefits across gastrointestinal, immune, metabolic, dermatological, and neuropsychological domains; evaluate clinical evidence; present key strains associated with major health conditions; assess safety and regulatory considerations; and discuss future directions including personalized microbiome-based approaches and next-generation probiotic technologies. Through this integrated analysis, the review provides a holistic understanding of probiotics and their expanding relevance to human health.

2. Probiotic Types, Characteristics, and Mechanisms

Probiotics encompass a broad spectrum of microorganisms that confer health benefits when administered in adequate amounts, and their diversity reflects the complexity of the human microbiome itself [17]. These microorganisms include not only lactic acid–producing bacteria traditionally associated with fermented foods but also spore-forming *Bacillus* species, beneficial streptococci, and increasingly explored yeast strains such as *Saccharomyces boulardii* (**Table 1**) [18]. Each group possesses distinct physiological traits, survival capacities, and mechanisms of action, making strain-level characterization essential for determining therapeutic relevance [19]. As microbiome science advances, the

classification of probiotics has shifted from broad genus-level categories toward highly specific strain-level assessments, emphasizing the importance of genomic stability, functional attributes, and host interaction capabilities [20]. The following subsections explore the taxonomy, safety criteria, and mechanistic foundations that define the functional potential of probiotic strains.

Table 1: Major Probiotic Strains and Their Primary Health Benefits

Probiotic Strain	Health Benefits	Mechanism of Action	Recommended Dosage	Strength of Evidence	Clinical Evidence	Reference
Lactobacillus rhamnosus	Improves gut health, prevents diarrhea, strengthens immune function	Enhances epithelial barrier, produces lactic acid, modulates immune system	1–10 billion CFU/day	High	Clinical trials show effectiveness in reducing the incidence of antibiotic-associated diarrhea (AAD) and improving gut health	[21]
Bifidobacterium longum	Reduces symptoms of IBS, boosts gut microbiota, supports immune health	Produces SCFAs, modulates gut microbiota, supports immune tolerance	1–5 billion CFU/day	Moderate	Clinical evidence supports improvements in IBS symptoms and inflammatory markers	[22]
Saccharomyces boulardii	Prevents and treats diarrhea, reduces IBD symptoms	Competitive exclusion, enhances gut barrier, reduces inflammation	250–500 mg 2–3 times/day	High	Well-documented in the prevention of AAD and Clostridium difficile infection	[23]
Streptococcus thermophilus	Aids lactose digestion, supports immune health	Ferments lactose, produces antimicrobial peptides, modulates gut flora	1–5 billion CFU/day	Moderate	Evidence in lactose-intolerant individuals showing improved digestion and immune function	[24]
Lactobacillus casei	Enhances gut motility, reduces inflammation, improves immunity	Produces lactic acid, promotes healthy microbiota, stimulates immune responses	5–10 billion CFU/day	High	Effective in managing symptoms of IBS and IBD, supports inflammatory balance in clinical settings	[25]
Bacillus coagulans	Supports digestion, enhances immune response, improves gut health	Forms spores, survives harsh environments, modulates gut microbiota	1–5 billion CFU/day	Moderate	Clinical studies show significant improvements in IBS, IBS-C, and general gut health	[26]
Bifidobacterium infantis	Improves symptoms of colic and constipation	Modulates immune system, increases gut motility, reduces gas production	1–5 billion CFU/day	Low	Well-established in pediatric gastrointestinal health, particularly for colic	[27]
Enterococcus faecium	Improves intestinal barrier function, reduces pathogen colonization	Inhibits pathogens via bacteriocin production, enhances gut barrier integrity	5–10 billion CFU/day	Low	Evidence in improving gut flora balance and reducing pathogen load in clinical trials	[28]

2.1 Classification and Key Strains

2.1.1 Bacterial and Yeast Probiotics

Bacterial probiotics represent the most extensively studied category, with *Lactobacillus* and *Bifidobacterium* at the forefront due to their long history of safe consumption and their natural prevalence in the human gastrointestinal and urogenital tracts [29]. *Lactobacillus* species are well known for producing lactic acid, contributing to pathogen suppression and pH regulation within the gut, while Bifidobacterium species play a crucial role in metabolizing complex carbohydrates, maintaining immune tolerance, and supporting early-life gut development [30]. Beyond these dominant genera, other bacterial groups such as *S. thermophilus, E. faecium, P. freudenreichii*, and various *Bacillus* strains have gained increasing attention. Spore-forming *Bacillus* species, in particular, offer exceptional resilience against environmental stressors, allowing them to survive gastric acidity and reach the intestine intact, where they germinate and exert metabolic and immunological benefits [31].

Yeast probiotics, though fewer in number, offer unique advantages that complement bacterial strains. *S. boulardii* is the most clinically validated yeast probiotic and is widely used for managing antibiotic-associated diarrhea, gastrointestinal infections, and inflammatory gastrointestinal conditions [32]. Its ability to survive antibiotic exposure, produce trophic factors that enhance brush-border enzyme activity, and modulate inflammatory signaling pathways distinguishes it from bacterial probiotics [33]. Yeasts also lack the cell structures associated with horizontal gene transfer, reducing the risk of transmitting antibiotic-resistance genes. Together, bacterial and yeast probiotics represent a multifaceted therapeutic resource, and their diversity highlights the importance of selecting strains based on targeted physiological outcomes rather than relying on broad generalizations about genera (**Figure 1**).



Figure 1: Classification and key strains used as probiotics

2.1.2 Selection and Safety Criteria

The selection of probiotic strains is governed by internationally recognized criteria established by bodies such as FAO/WHO, the European Food Safety Authority, and regulatory agencies across different regions [34]. These guidelines mandate that probiotic strains must be precisely identified using genomic techniques, demonstrate the ability to survive and function within the gastrointestinal environment, and show evidence of beneficial effects through mechanistic studies and clinical trials [35]. Strain-specific documentation is critical, as closely related strains often exhibit significantly different biological activities. Essential functional characteristics include acid and bile tolerance, adhesion to epithelial tissues, antimicrobial activity, and immune-modulating potential. The selection process ensures that only strains with validated biological activity and technological stability are used in supplements and functional foods [36].

Safety assessment is an integral component of probiotic characterization. Many commonly used strains are designated GRAS (Generally Recognized As Safe) or QPS (Qualified Presumption of Safety), based on historical consumption and accumulated toxicological data [37]. However, safety evaluations extend beyond general status and include screening for virulence factors, hemolytic properties, toxin genes, and transferable antibiotic-resistance determinants [38]. Since probiotics interact intimately with the host's immune system and microbiota, it is crucial to assess their behavior in vulnerable populations, including neonates, pregnant women, and immunocompromised patients [39]. Variations in regulatory standards across countries mean that probiotic manufacturers must comply with region-specific requirements for strain identity, dose, labeling, and health claims [40]. These safety and regulatory frameworks collectively ensure that probiotics used in clinical or nutritional applications provide benefits without posing health risks.

2.2 Core Mechanisms of Action

2.2.1 Microbiota Modulation and Colonization Resistance

A central mechanistic principle of probiotic function is their capacity to modulate the structure and activity of the gut microbiota [41]. Probiotics compete directly with pathogenic microorganisms for ecological niches, including adhesion sites on intestinal epithelial cells, thereby reducing the ability of harmful bacteria to colonize the gut [42]. This competitive exclusion is reinforced by the production of organic acids, such as lactic and acetic acid, which lower gut pH and create an unfavorable environment for pathogenic species [43]. Many probiotic strains also secrete bacteriocins, small antimicrobial peptides that target specific pathogenic organisms-enhancing the protective effect. Through these interactions, probiotics support microbial diversity

and foster a stable gut ecosystem that resists dysbiosis triggered by antibiotics, infections, stress, or poor diet [44]. These ecological and metabolic modulation positions probiotics as key players in restoring gut homeostasis and preventing a cascade of downstream health issues linked to microbial imbalance. By shaping microbial communities and influencing microbe–microbe interactions, probiotics contribute to improved gastrointestinal function and broader systemic benefits (**Figure 2**).



Figure 2: Mechanisms of action of probiotics. Schematic diagram illustrating potential or known mechanisms whereby probiotic bacteria might impact on the microbiota. These mechanisms include (1) competition for dietary ingredients as growth substrates, (2) bioconversion of sugars into fermentation products with inhibitory properties, (3) production of growth substrates (4) direct antagonism by bacteriocins, (5) competitive exclusion for binding sites, (6) improved barrier function, (7) reduction of inflammation, thus altering intestinal properties for colonization and persistence within, and (8) stimulation of innate immune response. Figure adopted from www.customprobiotics.com.

2.2.2 Metabolite Production and Host Signaling

In addition to direct effects on the microbiota, probiotics exert biological activity by producing a wide range of metabolites that act as chemical messengers within the host. SCFAs such as butyrate, propionate, and acetate support epithelial integrity, regulate inflammation, and influence appetite and energy metabolism [45]. Other metabolites, including vitamins, conjugated linoleic acid, and antimicrobial compounds, contribute to host nutrient status and pathogen defense. Some probiotic strains also degrade toxins, reduce oxidative stress, and facilitate the breakdown of complex dietary fibers, enhancing digestive efficiency and metabolic regulation [46].

Several probiotic strains engage directly with receptors on immune cells, including Toll-like receptors, influencing cytokine production and guiding the balance between pro-inflammatory and anti-inflammatory responses [47]. Certain strains modulate neurotransmitter production or regulate the precursors of serotonin, GABA, or dopamine, thereby participating in gut-brain communication and influencing psychological well-being [48]. Other probiotics impact endocrine signaling, lipid metabolism, and glycemic control through interactions with metabolic regulators [49]. Together, these mechanistic pathways reveal that probiotics operate not merely as transient microorganisms but as biologically active agents capable of orchestrating complex, multi-system interactions within the human body.

2.3 Synbiotics

Synbiotics refer to the combination of probiotics (beneficial live microorganisms) and prebiotics (non-digestible food ingredients that selectively stimulate the growth or activity of beneficial microbes). This synergistic combination is designed to enhance the effectiveness of both components, as prebiotics provide the necessary substrate to support the survival and growth of probiotics in the gut, while probiotics help to better utilize and metabolize prebiotics. Synbiotics aim to improve gut health by not only replenishing beneficial microbes but also creating an environment that supports their activity and long-term colonization [50, 51]. Synbiotics have been explored for their potential benefits in metabolic health, skin conditions, and mental health. For example, synbiotics that include specific strains in combination with inulin or fructooligosaccharides (FOS) have shown positive effects on reducing inflammation, improving insulin sensitivity, and supporting skin health [52]. Furthermore, synbiotics are gaining attention for their potential role in mental health and mood regulation, especially in conditions like anxiety, depression, and stress-related disorders. Although the clinical evidence for synbiotics is still emerging, early studies suggest that their therapeutic potential may surpass that of individual probiotics and prebiotics, especially in chronic conditions with multifactorial etiologies. Future research should focus on optimizing synbiotic formulations, determining effective dosages, and understanding the complex interactions between probiotics, prebiotics, and host-specific factors.

However, the evidentiary base for synbiotics should be interpreted with caution, because the term encompasses heterogeneous strain-substrate combinations that are not biologically equivalent. Reported outcomes are frequently contingent on probiotic strain identity, prebiotic type and dose, baseline dietary patterns, and inter-individual microbiome differences, which collectively contribute to substantial variability in efficacy across trials. Moreover, many clinical studies remain limited by short intervention periods, modest sample sizes, and inconsistent endpoint selection, reducing comparability and limiting inference about durability of effects. Importantly, claims of sustained intestinal "colonization" are not always supported; for many strains, observed benefits may reflect transient functional modulation rather than stable, long-term community restructuring. Accordingly, future investigations should emphasize adequately powered randomized controlled designs, explicitly classify products as synergistic versus complementary based on demonstrated metabolic compatibility, and incorporate mechanistic biomarkers alongside standardized clinical outcomes to delineate responder profiles and strengthen causal interpretation.

3. Functional Benefits of Probiotics on Human Health

Probiotics exert a wide range of functional benefits across multiple physiological systems, reflecting their multifaceted roles in maintaining gastrointestinal homeostasis, supporting immune responses, regulating metabolism and influencing dermatological and neuropsychological health [53]. Their ability to modulate microbial communities, strengthen epithelial defenses, produce bioactive metabolites, and regulate host signaling pathways positions them as powerful agents for both preventive and therapeutic applications [54]. Understanding these functional benefits provides the foundation for targeted clinical applications and informs the development of next-generation probiotics for personalized health interventions (**Table 2**).

Table 2: Clinical Applications of Probiotics in Major Human Health Conditions

Health Condition	Probiotic Strain(s)	Mechanism of Action	Clinical Evidence	References
Irritable Bowel Syndrome (IBS)	*Lactobacillus spp., Bifidobacterium spp.*	Modulates gut motility, reduces visceral hypersensitivity	Strain-specific effectiveness shown in reducing IBS-related symptoms	[55]
Inflammatory Bowel Disease (IBD)	*Lactobacillus rhamnosus, Bifidobacterium longum*	Reduces inflammation, promotes mucosal healing, modulates immune response	Studies demonstrate the ability to reduce flare-ups, maintain remission, reduce inflammation	[56]
Antibiotic-Associated Diarrhea (AAD)	*Saccharomyces boulardii, Lactobacillus GG*	Prevents pathogen overgrowth, restores beneficial gut flora, reduces microbial translocation	Strong evidence supporting the prevention and treatment of AAD	[57]
Obesity and Metabolic Syndrome	*Lactobacillus gasseri, Bifidobacterium animalis*	Modulates lipid metabolism, reduces visceral fat, enhances insulin sensitivity	Clinical trials showing reduction in body fat percentage, improved insulin sensitivity	[58]
Skin Health (Eczema, Acne, Psoriasis)	*Lactobacillus rhamnosus, Bifidobacterium bifidum*	Modulates systemic inflammation, regulates immune responses	Evidence in improving skin hydration, reducing eczema symptoms	[59]
Mental Health (Anxiety, Depression, Stress)	*Lactobacillus helveticus, Bifidobacterium longum*	Modulates the gut–brain axis, produces neurotransmitters (GABA, serotonin), reduces cortisol	Revealed potential in improving mood, reducing anxiety, cognitive function	[60]
Respiratory Infections	*Lactobacillus casei, Bifidobacterium animalis*	Stimulates immune responses, enhances mucosal immunity	Reduced incidence of upper respiratory infections	[25]

3.1 Gastrointestinal Health

3.1.1 Digestive Disorders (IBS, IBD, AAD)

In irritable bowel syndrome (IBS), probiotics help modulate gut motility and alleviate symptoms such as bloating and abdominal pain [61]. These improvements are largely attributed to the ability of probiotics to regulate microbial fermentation, reduce gas-producing organisms, and influence neuromuscular signaling pathways. Clinical trials have shown that specific strains of Lactobacillus and Bifidobacterium improve overall IBS symptom severity, highlighting the importance of strain-specific interventions [62]. Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, is characterized by chronic inflammation and an impaired intestinal barrier [63]. Probiotics contribute to IBD management by reducing inflammatory cytokines, enhancing mucosal healing, and promoting regulatory T-cell activation [64]. Certain strains also downregulate NF-κB and other inflammatory pathways, helping restore immune tolerance. Although probiotics are not a replacement for conventional therapies, they serve as supportive agents that may reduce disease flares and maintain remission in select individuals [65]. Antibiotic-associated diarrhea (AAD) represents another well-documented therapeutic area where probiotics are highly effective [66]. By replenishing beneficial microbes disrupted by antibiotic therapy and preventing pathogenic overgrowth-particularly Clostridioides difficile-probiotics significantly reduce the incidence and severity of AAD, making them an essential adjunct in antibiotic regimens.

However, clinical outcomes for IBS and IBD are not uniform across trials. Meta-analyses generally report overall symptom improvement in IBS, but with substantial heterogeneity and frequent null findings-suggesting that benefits are often strain- and endpoint-specific rather than a class effect [12,102]. For IBD, evidence appears more consistent for select settings (e.g., ulcerative colitis remission maintenance or pouchitis) than for Crohn's disease, and variability in enrolled populations and outcome measures complicates comparisons across studies [50,65]. Likely contributors to these inconsistencies include differences in strain selection/combination, viable dose (CFU), formulation and duration, baseline disease severity, concomitant therapies, and trial design (sample size, follow-up length, and outcome definitions) [12,62].

3.1.2 Strengthening the Gut Barrier

The integrity of the intestinal barrier is essential for maintaining gastrointestinal and systemic health, and probiotics play a significant role in reinforcing this barrier at multiple levels [67]. The gut barrier is composed of mucus layers, epithelial cells, tight junctions, and immune defenses that work together to regulate microbial interactions and prevent pathogen translocation [68]. Probiotics enhance the expression of tight-junction proteins thereby strengthening the epithelial barrier and reducing intestinal permeability [69]. This is particularly important in conditions like leaky gut syndrome, celiac disease, and chronic inflammatory disorders, where impaired barrier function leads to heightened immune activation and systemic inflammation [70].

Additionally, probiotics stimulate the production of mucins, glycoproteins that form a protective layer over the intestinal epithelium. Increased mucin secretion enhances the barrier against pathogens and reduces the risk of bacterial translocation [71]. Some probiotic strains also produce short-chain fatty acids, notably butyrate, which serve as an energy source for colonocytes and promote epithelial regeneration. These combined actions support a robust mucosal defense system that protects against infections, reduces antigenic load, and maintains gastrointestinal equilibrium [72]. The ability of probiotics to reinforce barrier function has profound implications for preventing chronic inflammation, metabolic dysfunction, and autoimmune responses linked to barrier impairment (Figure 3).

3.2 Immune and Anti-Inflammatory Effects

3.2.1 Immune Regulation and Cytokine Balance

Probiotics exert significant immunomodulatory effects by interacting with immune cells and influencing cytokine signaling pathways [73]. They engage with pattern recognition receptors, including Toll-like receptors on epithelial and immune cells, which modulate downstream responses such as cytokine production, antigen presentation, and activation of innate and adaptive immunity [74]. Certain probiotic strains promote a shift from pro-inflammatory responses toward regulatory pathways by enhancing the production of IL-10 and other anti-inflammatory cytokines [75]. This makes them particularly valuable in conditions characterized by immune dysregulation, including allergies, respiratory infections, and autoimmune disorders.

Probiotics influence the balance between different T-cell subsets, including Th1, Th2, Th17, and regulatory T cells [76]. This balance is crucial for maintaining immune homeostasis and preventing excessive inflammatory reactions. For example, probiotics can suppress Th17-mediated inflammation while supporting Treg expansion, contributing to reduced tissue damage and improved immune tolerance [77]. These effects help explain the therapeutic potential of probiotics in conditions like atopic dermatitis, asthma, and low-grade systemic inflammation. Through their immunological interactions, probiotics enhance overall immune resilience, reducing susceptibility to infections and supporting long-term health.

3.2.2 Antioxidant and Anti-Inflammatory Responses

Oxidative stress and chronic inflammation are key contributors to the pathogenesis of numerous chronic diseases, including cardiovascular disorders, neurodegeneration, and metabolic syndrome [78]. Probiotics help counteract these processes through both direct and indirect mechanisms [10]. Certain strains produce antioxidant enzymes, such as superoxide dismutase and glutathione peroxidase, which neutralize reactive oxygen species and protect cellular structures from oxidative damage. Others stimulate endogenous antioxidant pathways within host tissues, enhancing overall oxidative defense.

In addition to their antioxidant effects, probiotics reduce the expression of pro-inflammatory cytokines while promoting anti-inflammatory mediators [79]. These immunological shifts help alleviate symptoms of chronic inflammation and reduce systemic inflammatory load. Probiotics also help normalize the gut microbiota, reducing endotoxin-producing bacteria and thus lowering circulating lipopolysaccharides (LPS) that contribute to metabolic inflammation [80]. Together, these antioxidant and anti-inflammatory properties illustrate the potential of probiotics as supportive agents in chronic disease prevention.

3.3 Metabolic and Systemic Health

3.3.1 Obesity, Diabetes, and Metabolic Regulation

Probiotics influence metabolic health through effects on nutrient absorption, energy harvesting, lipid metabolism, and hormonal signaling. Certain strains enhance the production of SCFAs, which regulate appetite, improve insulin sensitivity, and modulate hepatic lipid synthesis [81]. Probiotics also contribute to improved glycemic control by influencing incretin hormones such as GLP-1 and PYY, which regulate insulin secretion and appetite [82]. Clinical studies demonstrate that probiotic supplementation can reduce fasting glucose, improve insulin resistance indices, and support weight management when combined with lifestyle interventions [83]. Probiotics also affect adipocyte metabolism by modulating genes involved in fat storage and lipolysis. These metabolic interactions have implications for managing obesity, metabolic syndrome, and type 2 diabetes [84]. While probiotics are not standalone treatments, they complement dietary and pharmacological therapies, providing an accessible and low-risk strategy for improving metabolic outcomes.

At the same time, clinical trial findings for obesity- and diabetes-related outcomes are mixed. Reviews of human studies often show modest average improvements in glycemic control and some anthropometric markers, but also highlight high between-study heterogeneity and many trials reporting no significant benefit [83,12]. These discrepancies likely reflect strain-dependent metabolic mechanisms, differences in dose, adherence, and intervention duration, the presence (or absence) of co-interventions such as diet and exercise, medication use, and variability in participant phenotype and baseline microbiome status, along with inconsistent endpoints and reporting practices [84,13].

3.3.2 Cardiovascular and Lipid Profile Benefits

Cardiovascular health is closely linked to metabolic function, inflammation, and gut microbiota composition [85]. Probiotics contribute to cardiovascular well-being by lowering LDL cholesterol, reducing systemic inflammation, and improving endothelial function [86]. The cholesterol-lowering effects of probiotics are mediated by bile salt hydrolase activity, which reduces the reabsorption of bile acids and promotes cholesterol utilization for bile synthesis. Additionally, probiotics influence lipid metabolism by modulating hepatic gene expression and reducing circulating triglycerides. Probiotics also support cardiovascular health through anti-inflammatory actions and improvements in vascular function [87]. Chronic inflammation is a major contributor to atherosclerosis, and probiotics help reduce inflammatory mediators involved in plaque formation [88]. Some strains also produce metabolites that enhance nitric oxide availability, improving blood vessel relaxation and reducing blood pressure. These combined effects demonstrate the potential of probiotics as adjunctive therapies for cardiovascular risk reduction.

3.4 Skin and Gut–Brain Axis

3.4.1 Skin Health and Dermatological Effects

Probiotics influence skin health through their ability to regulate systemic inflammation, modulate immune responses, and support the gut-skin axis [89]. The gut–skin connection is mediated by microbial metabolites, immune signaling molecules, and inflammatory mediators that impact skin barrier function and tissue repair. Probiotics help restore balance in immune pathways implicated in atopic dermatitis, psoriasis, and acne, leading to reductions in symptoms such as redness, itching, and inflammation. Some strains enhance skin hydration and reduce transepidermal water loss by strengthening epithelial integrity [90].

Additionally, probiotics contribute to skin health by regulating lipid metabolism and producing metabolites that support barrier recovery. The reduction of systemic inflammatory markers and oxidative stress further promotes healthy skin physiology [91]. Clinical studies have shown that oral probiotic supplementation can improve outcomes in acne and eczema, while topical probiotics offer additional benefits through direct interactions with the skin microbiome [92]. Together, these effects highlight the potential of probiotics as multi-targeted agents for dermatological care.

3.4.2 Mental Health, Mood, and Cognitive Effects

Probiotics play an important role in mental health through their involvement in the gut–brain axis, a bidirectional communication system linking the gastrointestinal tract to the central nervous system [93]. Specific probiotic strains, often called psychobiotics, can influence psychological well-being by producing neurotransmitters such as GABA, serotonin, and dopamine or by regulating their precursors. These interactions help modulate mood, anxiety, stress responses, and cognitive function. Probiotics also reduce systemic inflammation and regulate HPA-axis activity, further influencing psychological resilience [94]. Clinical studies illustrate that probiotics can alleviate symptoms of mild to moderate depression, reduce stress-induced cortisol elevation, and improve cognitive performance in certain populations [95]. By modulating neural signaling and reducing inflammation, probiotics exert protective effects on brain health and support emotional stability [93]. Although research in this area is still growing, psychobiotics represent a promising new avenue for mental health interventions, particularly as part of integrative approaches.



Figure 3: Functional benefits of probiotics

4. Applications, Safety, and Future Perspectives

Probiotics have transitioned from traditional dietary components to scientifically validated therapeutic agents with applications across clinical nutrition, preventive medicine, and personalized healthcare [96]. Their incorporation into foods, supplements, and therapeutic regimens reflects growing evidence of their capacity to modulate gut microbiota, support metabolic and immune functions, and influence systemic health [97]. At the same time, the expanding market for probiotic products underscores the importance of understanding formulation stability, strain viability, safety considerations, and global regulatory frameworks [98]. As the field evolves, probiotics are increasingly integrated into innovative delivery systems, next-generation microbial therapeutics, and precision nutrition strategies. This section examines the current applications of probiotics, and outlines emerging directions that are reshaping the future of probiotics.

4.1 Probiotics in Foods, Supplements, and Clinical Use

Probiotics are widely incorporated into fermented foods, functional beverages, and dietary supplements, serving as accessible tools for enhancing gut health and supporting overall well-being [99]. Fermented products such as yogurt, kefir, miso, kimchi, and kombucha provide natural sources of beneficial microbes, while encapsulated supplements offer more precise dosing and strain-specific formulations [100]. The viability of probiotic organisms during production, storage, and gastrointestinal transit is essential for delivering health benefits, and modern technologies including microencapsulation, freeze-drying, and spore-forming strains, which have greatly enhanced the stability and survivability of probiotics in various delivery formats [101]. Additionally, food-based probiotic interventions offer synergistic benefits by delivering bioactive compounds, fibers, and prebiotics that support microbial growth and metabolic activity.

In clinical settings, probiotics are increasingly used as adjunctive therapies for digestive disorders, metabolic syndrome, allergies, and immune conditions. Physicians prescribe strain-specific probiotics for antibiotic-associated diarrhea, atopic dermatitis, irritable bowel syndrome, and infant colic, among other conditions [102]. These applications rely on clinical evidence demonstrating measurable improvements in symptom severity, microbial balance, immune regulation, and barrier integrity. The integration of probiotics into medical nutrition therapy reflects a paradigm shift toward microbiome-centered healthcare, where dietary and microbial interventions are recognized as key components of disease prevention and recovery [103]. As more clinical trials identify strain-specific benefits and optimal dosing strategies, the role of probiotics in evidence-based healthcare continues to expand.

4.2 Safety, Risks, and Regulatory Challenges

Although probiotics are generally considered safe, particularly those with GRAS or QPS status, safety evaluations remain essential due to the biological complexity of host–microbe interactions [104]. Most probiotics pose minimal risk to healthy individuals; however, immunocompromised patients, elderly

populations, neonates, and individuals with central venous catheters may be more susceptible to rare complications such as bacteremia or fungemia. Strain identity, host susceptibility, product purity, and manufacturing quality all influence probiotic safety [105]. The possibility of horizontal gene transfer underscores the need for genetic screening and stringent quality control during production. Ensuring strain stability, genomic integrity, and absence of virulence factors is critical to maintaining safety standards across the industry.

Regulatory frameworks for probiotics vary significantly across countries, creating challenges in standardizing product quality, labeling, health claims, and clinical validation requirements [106]. In some regions, probiotics are regulated as foods or supplements, while in others they fall under pharmaceutical or therapeutic categories, requiring rigorous clinical testing [107]. These disparities can lead to inconsistencies in product potency, accuracy of strain labeling, and consumer expectations. There is a growing call for global harmonization of probiotic regulations, particularly regarding strain identification, minimum viable counts, and evidence for functional claims [108]. Improved regulatory oversight will help ensure that probiotics marketed to consumers are safe, effective, and scientifically substantiated.

While probiotics are generally safe in the short term, limited data exist on their long-term safety, particularly with engineered strains, which may pose unforeseen risks such as gut microbiome alterations or metabolic disruptions. Ongoing post-marketing surveillance is crucial to identify any long-term adverse effects. Additionally, clearer labeling is needed, as many probiotic products lack detailed information on strain-specific efficacy, dosages, and storage conditions, leading to consumer confusion. Regulatory bodies should ensure labels provide accurate strain identity, viable counts, and evidence-supported claims to help consumers make informed choices.

4.3 Next-Generation Directions

4.3.1 Personalized Microbiome Therapies

As understanding of the human microbiome deepens, probiotics are increasingly viewed through the lens of personalized medicine. Individual differences in microbiome composition, genetics, diet, and lifestyle can significantly influence probiotic response, highlighting the need for tailored interventions [109]. Personalized microbiome profiling allows clinicians and researchers to identify deficiencies or imbalances and recommend strain-specific therapies that target specific pathways or physiological needs [110]. Emerging tools including AI-driven predictive models, metagenomic sequencing, and metabolomic signatures enable the design of more precise probiotic regimens with higher therapeutic potential [111]. The shift toward personalized probiotics represents a transformative development, offering targeted interventions capable of addressing unique health challenges and optimizing outcomes at the individual level.

4.3.2 Engineered and Next-Generation Probiotics

Next-generation probiotics, including *Akkermansia muciniphila, Faecalibacterium prausnitzii*, and engineered microbial strains, represent the future of microbiome therapeutics [112]. These organisms possess potent physiological effects, such as enhancing mucin production, regulating inflammation, and producing beneficial metabolites, but often require specialized cultivation and delivery systems [113]. Advances in synthetic biology have opened new possibilities for engineering probiotics with enhanced therapeutic functions, such as targeted metabolite production, pathogen detection and neutralization, or delivery of therapeutic molecules. Engineered strains may be designed to modulate specific cellular pathways, degrade harmful metabolites, or support immune regulation in disease-specific contexts.

These next-generation approaches promise to overcome limitations of traditional probiotics by offering higher specificity, measurable activity, and therapeutic precision [114]. However, they also raise new considerations related to safety, ethical oversight, and regulatory classification. As engineered probiotics move closer to clinical applications, robust frameworks will be required to evaluate their long-term effects, ecological consequences, and interactions within the microbiome [115]. The convergence of synthetic biology, computational modeling, and microbiome science is therefore poised to redefine the scope of probiotic research and open new opportunities for treating complex diseases through targeted microbial interventions.

5. Conclusion

Probiotics have progressed from traditional components of fermented foods to scientifically investigated agents with potential to influence human health across multiple physiological systems. Advances in microbiome research have clarified key mechanisms through which specific probiotic strains modulate gut microbiota composition, enhance intestinal barrier function, and regulate immune, metabolic, and neuroendocrine pathways. These strain-dependent effects underpin reported benefits in gastrointestinal, metabolic, dermatological, and mental health outcomes, supporting the growing interest in probiotics within preventive healthcare and medical nutrition therapy.

Despite these advances, important challenges remain. Clinical evidence is inconsistent for several indications, reflecting variability in probiotic strains, dosages,

treatment durations, and study designs. Additional concerns include limited product standardization, the absence of harmonized global regulatory frameworks, and safety considerations in vulnerable populations. Addressing these limitations will require well-designed clinical trials with standardized protocols and clearly defined outcome measures.

Future research should prioritize personalized probiotic strategies that account for individual microbiota profiles, genetic factors, and specific disease contexts. In parallel, emerging technologies such as metagenomics, artificial intelligence, and synthetic biology are enabling the development of next-generation and engineered probiotics with more targeted therapeutic potential. Integrating these approaches may help resolve current inconsistencies in clinical outcomes and advance the translation of probiotic research into effective, evidence-based health interventions.

6. References

Abouelela, M.E. and Y.A. Helmy, Next-generation probiotics as novel therapeutics for improving human health: current trends and future perspectives. Microorganisms, 2024. 12(3): p. 430.

Gasbarrini, G., F. Bonvicini, and A. Gramenzi, Probiotics history. Journal of clinical gastroenterology, 2016. 50: p. S116-S119.

Malla, M.A., et al., Exploring the human microbiome: the potential future role of next-generation sequencing in disease diagnosis and treatment. Frontiers in immunology, 2019. 9: p. 2868.

Liu, Y., D.Q. Tran, and J.M. Rhoads, Probiotics in disease prevention and treatment. The Journal of Clinical Pharmacology, 2018. 58: p. S164-S179.

Papadimitriou, K., et al., Discovering probiotic microorganisms: in vitro, in vivo, genetic and omics approaches. Frontiers in microbiology, 2015. 6: p. 58.

Sánchez, B., et al., Probiotics, gut microbiota, and their influence on host health and disease. Molecular nutrition & food research, 2017. 61(1): p. 1600240.

Aziz, T., et al., Elucidating the role of diet in maintaining gut health to reduce the risk of obesity, cardiovascular and other age-related inflammatory diseases: Recent challenges and future recommendations. Gut Microbes, 2024. 16(1): p. 2297864.

Jena, R., et al., Bifidobacteria in antibiotic-associated dysbiosis: restoring balance in the gut microbiome. World Journal of Microbiology and Biotechnology, 2025. 41(8): p. 297.

Sun, X., et al., Unlocking gut-liver-brain axis communication metabolites: energy metabolism, immunity and barriers. npj Biofilms and Microbiomes, 2024. 10(1): p. 136.

Bermudez-Brito, M., et al., Probiotic mechanisms of action. Annals of Nutrition and Metabolism, 2012. 61(2): p. 160-174.

Thomas, C.M. and J. Versalovic, Probiotics-host communication: modulation of signaling pathways in the intestine. Gut microbes, 2010. 1(3): p. 148-163.

Rondanelli, M., et al., Using probiotics in clinical practice: Where are we now? A review of existing meta-analyses. Gut microbes, 2017. 8(6): p. 521-543.

Ayesiga, I., et al., Key regulatory aspects of prebiotics, probiotics, and synbiotics in the management of metabolic disorders, in Synbiotics in Metabolic Disorders. 2024, CRC Press. p. 214-244.

Chen, L., S. Xu, and J. Li, Recent advances in molecular imprinting technology: current status, challenges and highlighted applications. Chemical Society Reviews, 2011. 40(5): p. 2922-2942.

Rouanet, A., et al., Live biotherapeutic products, a road map for safety assessment. Frontiers in Medicine, 2020. 7: p. 237.

Gupta, D.K., et al., Ensuring safety and efficacy in combination products: regulatory challenges and best practices. Frontiers in Medical Technology, 2024. 6: p. 1377443.

Zommiti, M., M.G. Feuilloley, and N. Connil, Update of probiotics in human world: a nonstop source of benefactions till the end of time. Microorganisms, 2020. 8(12): p. 1907.

Al-Kharousi, Z.S., Highlighting Lactic Acid Bacteria in Beverages: Diversity, Fermentation, Challenges, and Future Perspectives. Foods, 2025. 14(12): p. 2043.

Yan, Y., et al., Strain-level epidemiology of microbial communities and the human microbiome. Genome medicine, 2020. 12(1): p. 71.

Huys, G., et al., Microbial characterization of probiotics–Advisory report of the W orking G roup "8651 Probiotics" of the B elgian S uperior H ealth C ouncil (SHC). Molecular nutrition & food research, 2013. 57(8): p. 1479-1504.

Evans, M., et al., Effectiveness of Lactobacillus helveticus and Lactobacillus rhamnosus for the management of antibiotic-associated diarrhoea in healthy adults: a randomised, double-blind, placebo-controlled trial. British journal of Nutrition, 2016. 116(1): p. 94-103.

Dargenio, V.N., et al., Impact of Bifidobacterium longum Subspecies infantis on pediatric gut health and nutrition: Current evidence and future directions. Nutrients, 2024. 16(20): p. 3510.

Terciolo, C., M. Dapoigny, and F. Andre, Beneficial effects of Saccharomyces boulardii CNCM I-745 on clinical disorders associated with intestinal barrier disruption. Clinical and experimental gastroenterology, 2019: p. 67-82.

Huang, Y.-Y., et al., Metabolic properties, functional characteristics, and practical application of Streptococcus thermophilus. Food Reviews International, 2024. 40(2): p. 792-813.

Galdeano, C.M. and G. Perdigon, The probiotic bacterium Lactobacillus casei induces activation of the gut mucosal immune system through innate immunity. Clinical and vaccine immunology, 2006. 13(2): p. 219-226.

Zhou, Y., et al., Application of Bacillus coagulans in animal husbandry and its underlying mechanisms. Animals, 2020. 10(3): p. 454.

García-Santos, J.A., et al., Impact of probiotics on the prevention and treatment of gastrointestinal diseases in the pediatric population. International Journal of Molecular Sciences, 2023. 24(11): p. 9427.

Palkovicsné Pézsa, N., et al., Effect of Enterococcus faecium NCIMB 10415 on gut barrier function, internal redox state, proinflammatory response and pathogen inhibition properties in porcine intestinal epithelial cells. Nutrients, 2022. 14(7): p. 1486.

Maftei, N.-M., et al., The potential impact of probiotics on human health: an update on their health-promoting properties. Microorganisms, 2024. 12(2): p. 234.

Kailasapathy, K. and J. Chin, Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp. Immunology and cell biology, 2000. 78(1): p. 80-88.

Todorov, S.D., et al., Bacillus spore-forming probiotics: benefits with concerns? Critical Reviews in Microbiology, 2022. 48(4): p. 513-530.

Czerucka, D., T. Piche, and P. Rampal, yeast as probiotics–Saccharomyces boulardii. Alimentary pharmacology & therapeutics, 2007. 26(6): p. 767-778.

Raheem, A., et al., Modulatory effects of probiotics during pathogenic infections with emphasis on immune regulation. Frontiers in immunology, 2021. 12: p. 616713.

Zielińska, D. and D. Kołożyn-Krajewska, Food-origin lactic acid bacteria may exhibit probiotic properties. BioMed research international, 2018. 2018(1): p. 5063185.

Merenstein, D., et al., Emerging issues in probiotic safety: 2023 perspectives. Gut microbes, 2023. 15(1): p. 2185034.

Uhegwu, C.C. and C.K. Anumudu, Probiotic Potential of Traditional and Emerging Microbial Strains in Functional Foods: From Characterization to Applications and Health Benefits. Microorganisms, 2025. 13(11): p. 2521.

O'Connell Motherway, M., et al., Report of the Scientific Committee of the Food Safety Authority of Ireland on the Assessment of the safety of "probiotics" in food supplements. 2024, Wiley Online Library.

Chebotar, I., et al., Detection of virulence factors in opportunistic bacteria: advances, challenges, and practical implementation. Frontiers in Microbiology, 2025. 16: p. 1638925.

Slöcker-Barrio, M., J. López-Herce Cid, and M.J. Solana-García, The Interplay Between Nutrition and Microbiota and the Role of Probiotics and Symbiotics in Pediatric Infectious Diseases. Nutrients, 2025. 17(7): p. 1222.

PVS, V., et al., Probiotic Identity from Spore: Focus on Bacillus Probiotics, in Probiotics, Prebiotics, Synbiotics, and Postbiotics. 2023, Springer. p. 535-588.

Hemarajata, P. and J. Versalovic, Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation. Therapeutic advances in gastroenterology, 2013. 6(1): p. 39-51.

Van Zyl, W.F., S.M. Deane, and L.M. Dicks, Molecular insights into probiotic mechanisms of action employed against intestinal pathogenic bacteria. Gut microbes, 2020. 12(1): p. 1831339.

Dittoe, D.K., S.C. Ricke, and A.S. Kiess, Organic acids and potential for modifying the avian gastrointestinal tract and reducing pathogens and disease. Frontiers in veterinary science, 2018. 5: p. 216.

Anjana, a. and S.K. Tiwari, Bacteriocin-producing probiotic lactic acid bacteria in controlling dysbiosis of the gut microbiota. Frontiers in cellular and infection microbiology, 2022. 12: p. 851140.

Rekha, K., et al., Short-chain fatty acid: An updated review on signaling, metabolism, and therapeutic effects. Critical Reviews in Food Science and Nutrition, 2024. 64(9): p. 2461-2489.

Castro-López, C., et al., Key stress response mechanisms of probiotics during their journey through the digestive system: a review. Probiotics and antimicrobial proteins, 2023. 15(5): p. 1250-1270.

Gómez-Llorente, C., S. Munoz, and A. Gil, Role of Toll-like receptors in the development of immunotolerance mediated by probiotics. Proceedings of the Nutrition Society, 2010. 69(3): p. 381-389.

Margoob, M., S. Kouser, and N. Jan, Serotonin: The link between gut microbiome and brain, in Serotonin-Neurotransmitter and Hormone of Brain, Bowels and Blood. 2024, IntechOpen.

Gribble, F.M. and F. Reimann, Function and mechanisms of enteroendocrine cells and gut hormones in metabolism. Nature Reviews Endocrinology, 2019. 15(4): p. 226-237.

Akutko, K. and A. Stawarski, Probiotics, prebiotics and synbiotics in inflammatory bowel diseases. Journal of Clinical Medicine, 2021. 10(11): p. 2466.

Chlebicz-Wójcik, A. and K. Śliżewska, Probiotics, prebiotics, and synbiotics in the irritable bowel syndrome treatment: a review. Biomolecules, 2021. 11(8): p. 1154.

Pawar, N.A., et al., Fructooligosaccharide and Bacillus subtilis synbiotic combination promoted disease resistance, but not growth performance, is additive in fish. Scientific Reports, 2023. 13(1): p. 11345.

Yan, F. and D.B. Polk, Probiotics and probiotic-derived functional factors—Mechanistic insights into applications for intestinal homeostasis. Frontiers in immunology, 2020. 11: p. 1428.

Ghasemi, H., Microbial metabolites and immune modulation. Journal of Preventive and Complementary Medicine, 2024. 3(4): p. 209-211.

Bertuccioli, A., et al., Targeted probiotic therapy in irritable bowel syndrome: a clinical evaluation on Clostridium butyricum CBM588 and Bifidobacterium longum W11. Frontiers in Medicine, 2025. 12: p. 1604319.

Jadhav, A., et al., Reviewing the potential of probiotics, prebiotics and synbiotics: advancements in treatment of ulcerative colitis. Frontiers in Cellular and Infection Microbiology, 2023. 13: p. 1268041.

Doron, S., D.R. Snydman, and S.L. Gorbach, Lactobacillus GG: bacteriology and clinical applications. Gastroenterology Clinics, 2005. 34(3): p. 483-498.

Jiang, S., et al., Lactobacillus gasseri CKCC1913 mediated modulation of the gut–liver axis alleviated insulin resistance and liver damage induced by type 2 diabetes. Food & Function, 2023. 14(18): p. 8504-8520.

Lee, J.Y., et al., Anti-inflammatory response in TNFα/IFNγ-induced HaCaT keratinocytes and probiotic properties of Lacticaseibacillus rhamnosus MG4644, Lacticaseibacillus paracasei MG4693, and Lactococcus lactis MG5474. Journal of microbiology and biotechnology, 2023. 33(8): p. 1039.

Allen, A.P., et al., Bifidobacterium longum 1714 as a translational psychobiotic: modulation of stress, electrophysiology and neurocognition in healthy volunteers. Translational psychiatry, 2016. 6(11): p. e939-e939.

Dai, C., et al., Probiotics and irritable bowel syndrome. World Journal of Gastroenterology: WJG, 2013. 19(36): p. 5973.

McFarland, L.V., Efficacy of single-strain probiotics versus multi-strain mixtures: systematic review of strain and disease specificity. Digestive diseases and sciences, 2021. 66(3): p. 694-704.

Laukoetter, M.G., P. Nava, and A. Nusrat, Role of the intestinal barrier in inflammatory bowel disease. World journal of gastroenterology: WJG, 2008. 14(3): p. 401.

Guo, N. and L.l. Lv, Mechanistic insights into the role of probiotics in modulating immune cells in ulcerative colitis. Immunity, inflammation and disease, 2023. 11(10): p. e1045.

Dahiya, D. and P.S. Nigam, Biotherapy using probiotics as therapeutic agents to restore the gut microbiota to relieve gastrointestinal tract inflammation, IBD, IBS and prevent induction of cancer. International journal of molecular sciences, 2023. 24(6): p. 5748.

McFarland, L.V., Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future microbiology, 2008. 3(5): p. 563-578.

Mercado-Monroy, J., et al., Probiotics as modulators of intestinal barrier integrity and immune homeostasis: a comprehensive review. Journal of the Science of Food and Agriculture, 2025.

Gieryńska, M., et al., Integrity of the intestinal barrier: the involvement of epithelial cells and microbiota—a mutual relationship. Animals, 2022. 12(2): p. 145.

Wang, J., et al., Probiotic Lactobacillus plantarum promotes intestinal barrier function by strengthening the epithelium and modulating gut microbiota. Frontiers in microbiology, 2018. 9: p. 1953.

Fasano, A., All disease begins in the (leaky) gut:

role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases. F1000Research, 2020. 9: p. F1000 Faculty Rev-69.

Capaldo, C.T., D.N. Powell, and D. Kalman, Layered defense: how mucus and tight junctions seal the intestinal barrier. Journal of Molecular Medicine, 2017. 95(9): p. 927-934.

Mayer, L., H.A. Simpson, and J.A. Anderson, Mucosal immunity and gastrointestinal antigen processing. Journal of pediatric gastroenterology and nutrition, 2000. 30: p. S4-S12.

Azad, M.A.K., M. Sarker, and D. Wan, Immunomodulatory effects of probiotics on cytokine profiles. BioMed research international, 2018. 2018(1): p. 8063647.

Palm, N.W. and R. Medzhitov, Pattern recognition receptors and control of adaptive immunity. Immunological reviews, 2009. 227(1): p. 221-233.

Sichetti, M., et al., Anti-inflammatory effect of multistrain probiotic formulation (L. rhamnosus, B. lactis, and B. longum). Nutrition, 2018. 53: p. 95-102.

Omenetti, S. and T.T. Pizarro, The Treg/Th17 axis: a dynamic balance regulated by the gut microbiome. Frontiers in immunology, 2015. 6: p. 639.

Hu, Y., et al., Th17/Treg imbalance in inflammatory bowel disease: immunological mechanisms and microbiota-driven regulation. Frontiers in Immunology, 2025. 16: p. 1651063.

Rani, V., et al., Oxidative stress and metabolic disorders: Pathogenesis and therapeutic strategies. Life sciences, 2016. 148: p. 183-193.

Plaza-Diaz, J., et al., Modulation of immunity and inflammatory gene expression in the gut, in inflammatory diseases of the gut and in the liver by probiotics. World journal of gastroenterology: WJG, 2014. 20(42): p. 15632.

Festi, D., et al., Gut microbiota and metabolic syndrome. World journal of gastroenterology: WJG, 2014. 20(43): p. 16079.

Oudat, Q. and A. Okour, The role of probiotics in modulating gut microbiota and metabolic health for weight management: A mini review. Acta Microbiologica Hellenica, 2025. 70(1): p. 5.

De Silva, A. and S.R. Bloom, Gut hormones and appetite control: a focus on PYY and GLP-1 as therapeutic targets in obesity. Gut and liver, 2012. 6(1): p. 10.

Sáez-Lara, M.J., et al., Effects of probiotics and synbiotics on obesity, insulin resistance syndrome, type 2 diabetes and non-alcoholic fatty liver disease: a review of human clinical trials. International journal of molecular sciences, 2016. 17(6): p. 928.

Mensah, G.A., et al., Obesity, metabolic syndrome, and type 2 diabetes: emerging epidemics and their cardiovascular implications. Cardiology clinics, 2004. 22(4): p. 485-504.

Tang, W.W., T. Kitai, and S.L. Hazen, Gut microbiota in cardiovascular health and disease. Circulation research, 2017. 120(7): p. 1183-1196.

Pavlidou, E., et al., Clinical evidence on the potential beneficial effects of probiotics and prebiotics in cardiovascular disease. International Journal of Molecular Sciences, 2022. 23(24): p. 15898.

Grylls, A., K. Seidler, and J. Neil, Link between microbiota and hypertension: Focus on LPS/TLR4 pathway in endothelial dysfunction and vascular inflammation, and therapeutic implication of probiotics. Biomed Pharmacother, 2021. 137(111334): p. 10.1016.

Kong, P., et al., Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal transduction and targeted therapy, 2022. 7(1): p. 131.

Szántó, M., et al., Targeting the gut-skin axis—Probiotics as new tools for skin disorder management? Experimental dermatology, 2019. 28(11): p. 1210-1218.

Notay, M., et al., Probiotics, prebiotics, and synbiotics for the treatment and prevention of adult dermatological diseases. American journal of clinical dermatology, 2017. 18(6): p. 721-732.

Gao, T., et al., The role of probiotics in skin health and related gut–skin axis: A review. Nutrients, 2023. 15(14): p. 3123.

Mottin, V.H. and E.S. Suyenaga, An approach on the potential use of probiotics in the treatment of skin conditions: acne and atopic dermatitis. International journal of dermatology, 2018. 57(12): p. 1425-1432.

Ansari, F., et al., The role of probiotics and prebiotics in modulating of the gut-brain axis. Frontiers in nutrition, 2023. 10: p. 1173660.

Chen, Y., et al., Effects of psychological stress on inflammatory bowel disease via affecting the microbiota-gut-brain axis. Chinese Medical Journal, 2025. 138(06): p. 664-677.

Bloemendaal, M., et al., Probiotics-induced changes in gut microbial composition and its effects on cognitive performance after stress: exploratory analyses. Translational psychiatry, 2021. 11(1): p. 300.

Bubnov, R.V., et al., Probiotics and immunity: provisional role for personalized diets and disease prevention. EPMA Journal, 2015. 6(1): p. 14.

Cencic, A. and W. Chingwaru, The role of functional foods, nutraceuticals, and food supplements in intestinal health. Nutrients, 2010. 2(6): p. 611-625.

Mafe, A.N., et al., Genesis, health benefits, and future perspectives of probiotics: exploring endogenous and exogenous classes, innovations, and research gaps. Probiotics and Antimicrobial Proteins, 2025: p. 1-34.

Dahiya, D. and P.S. Nigam, Nutrition and health through the use of probiotic strains in fermentation to produce non-dairy functional beverage products supporting gut microbiota. Foods, 2022. 11(18): p. 2760.

Grujović, M.Ž., T. Semedo-Lemsaddek, and K.G. Marković, Application of Probiotics in Foods: A Comprehensive Review of Benefits, Challenges, and Future Perspectives. Foods, 2025. 14(17): p. 3088.

Sarao, L.K. and M. Arora, Probiotics, prebiotics, and microencapsulation: A review. Critical reviews in food science and nutrition, 2017. 57(2): p. 344-371.

McFarland, L.V., C.T. Evans, and E.J. Goldstein, Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis. Frontiers in medicine, 2018. 5: p. 124.

Christina, B., et al., The mechanisms and therapeutic potential of the microbiome-immune interface in cancer. Discover Biotechnology, 2025. 2(1): p. 25.

Arora, M., et al., Need and recommendations for universal guidelines on regulatory status and quality control/safety of probiotic products. Applied Clinical Research, Clinical Trials and Regulatory Affairs, 2019. 6(3): p. 231-249.

Zavišić, G., et al., Microbiological quality of probiotic products. Arhiv za farmaciju, 2023. 73(1): p. 17-34.

Arora, M. and A. Baldi, Comparative account of quality management and regulatory aspects of products with health claims: Existing approaches and future challenges for probiotics and herbal products. Applied Clinical Research, Clinical Trials and Regulatory Affairs, 2015. 2(3): p. 123-132.

Spacova, I., et al., Comparing technology and regulatory landscape of probiotics as food, dietary supplements and live biotherapeutics. Frontiers in Microbiology, 2023. 14: p. 1272754.

Liang, D., et al., Commercial probiotic products in public health: Current status and potential limitations. Critical reviews in food science and nutrition, 2024. 64(19): p. 6455-6476.

Shang, Z., L. Pai, and S. Patil, Unveiling the dynamics of gut microbial interactions: a review of dietary impact and precision nutrition in gastrointestinal health. Frontiers in Nutrition, 2024. 11: p. 1395664.

Schupack, D.A., et al., The promise of the gut microbiome as part of individualized treatment strategies. Nature reviews Gastroenterology & hepatology, 2022. 19(1): p. 7-25.

D'Urso, F. and F. Broccolo, Applications of artificial intelligence in microbiome analysis and probiotic interventions—An overview and perspective based on the current state of the art. Applied Sciences, 2024. 14(19): p. 8627.

Fakruddina, M., et al., Next-generation probiotics-the future of biotherapeutics. Microbial Bioactives, 2022. 5(1): p. 156-163.

Bakshani, C.R., et al., Evolutionary conservation of the antimicrobial function of mucus: a first defence against infection. npj Biofilms and Microbiomes, 2018. 4(1): p. 14.

Patra, D., Synthetic biology-enabled engineering of probiotics for precision and targeted therapeutic delivery applications. Exon, 2024. 1(2): p. 54-66.

Singh, V. and M. Rastogi, Future and Challenges of Microbiome Engineering, in Microbiome Engineering. 2024, CRC Press. p. 263-280.